Brief: IGC Pharma's Tgr-63 Preclinical Results Show Substantial Reduction In Amyloid Plaque, A Key Hallmark Of Alzheimer's Disease

IGC Pharma

25/06/2024 14:36

June 25 (Reuters) - IGC Pharma Inc  IGC.A :
    * IGC PHARMA'S TGR-63 PRECLINICAL RESULTS SHOW SUBSTANTIAL
REDUCTION IN AMYLOID PLAQUE, A KEY HALLMARK OF ALZHEIMER'S
DISEASE
    * IGC PHARMA INC: MOUSE STUDIES DEMONSTRATE SIGNIFICANT
REDUCTION
IN AMYLOID PLAQUE: 78% IN CORTEX AND 85% IN HIPPOCAMPUS
    * IGC PHARMA INC: EXPECTS TO BEGIN A PHASE 1 TRIAL FOR
TGR-63 IN
2025

Source text for Eikon:  ID:nBw5LXMjQa 
Further company coverage:  IGC.A 

 ((Reuters.Briefs@thomsonreuters.com;))